DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

LinksSchließen

Referenz

Martín M, Zielinski C, Ruíz-Borrego M. et al.
Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs).

San Antonio Breast Cancer Symposium 2019;
2019: GS2-07

Bibliographische Angaben herunterladen

Suchen in: